

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4994748

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT

**CONVEYING PARTY DATA**

Name	Execution Date
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD	01/31/2018

**RECEIVING PARTY DATA**

<b>Name:</b>	SAUL YEDGAR
<b>Street Address:</b>	1 TAIB STREET
<b>City:</b>	JERUSALEM
<b>State/Country:</b>	ISRAEL
<b>Postal Code:</b>	95405

**PROPERTY NUMBERS Total: 20**

Property Type	Number
Patent Number:	7034006
Patent Number:	7101859
Patent Number:	7141552
Patent Number:	7504384
Patent Number:	7608598
Patent Number:	7811999
Patent Number:	8076312
Patent Number:	8304395
Patent Number:	8372815
Patent Number:	8501701
Patent Number:	8859524
Patent Number:	8865681
Patent Number:	8883761
Patent Number:	8906882
Patent Number:	9040078
Application Number:	11984224
Application Number:	13779005
Application Number:	14071578
Application Number:	14527093
Application Number:	14478519

**PATENT**

**CORRESPONDENCE DATA****Fax Number:** (650)838-2001*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***Phone:** 650-838-2000**Email:** tami.tucker@alston.com**Correspondent Name:** CINDY CHANG**Address Line 1:** ALSTON & BIRD LLP**Address Line 2:** 101 SOUTH TRYON STREET, SUITE 4000**Address Line 4:** CHARLOTTE, NORTH CAROLINA 28280-4000**ATTORNEY DOCKET NUMBER:** 058522-478643**NAME OF SUBMITTER:** CINDY CHANG**SIGNATURE:** /Cindy Chang/**DATE SIGNED:** 06/06/2018**Total Attachments: 5**

source=AssignYissumtoYedgar#page1.tif

source=AssignYissumtoYedgar#page2.tif

source=AssignYissumtoYedgar#page3.tif

source=AssignYissumtoYedgar#page4.tif

source=AssignYissumtoYedgar#page5.tif

ASSIGNMENT

THIS ASSIGNMENT, is made from Yissum Research Development Company of the Hebrew University of Jerusalem, LTD, with a mailing address of (hereinafter referred to as the assignor); to Saul YEDGAR, with a mailing address of 1 Taib Street, Jerusalem, Israel 95405 (hereinafter referred to as the Assignee).

Whereas, Assignor claims and warrants that it owns all rights, title and interest of every kind, nature or description in and to the patents and patent applications listed in Schedule A hereto;

Whereas Assignor and Assignee wish for Assignee to acquire all rights in the patents and patent applications listed in Schedule A hereto for the convenience of the parties.

Now Therefore, for good and valuable consideration, receipt of which is hereby acknowledged, Assignor:

- 1. Has assigned, transferred, conveyed and sold and hereby assigns, transfers, conveys and sells to Assignee all rights, titles and interests in and to:
a. The Inventions throughout the world;
b. All of the Patents, the right to claim priority to the Patents and all U.S. and non-U.S. patents, registrations, validations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisions, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations of any of the Patents, and all rights under the International Convention for the Protection of Industrial Property, all for the full term or terms for which the same may be granted (collectively, the "Patent Rights"); and
c. All claims for damages by reason of past infringement of any of the Patent Rights (including provisional rights to reasonable royalties pursuant to 35 U.S.C. 154 (d)) and the right to sue for and collect such damages and royalties for Assignee's own use; and
2. Authorizes and requests the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue any and all of the Patent Rights to Assignee.
3. Agrees to sign and procure signature of, all papers and documents, for any proceeding in connection with said inventions, or said application for Letters Patent, or any proceeding in connection with Letters Patent for said inventions in any country, including interference proceedings, including without limitation, applications, declarations, oaths, assignments and petitions and, at Assignee's expense, perform any other acts necessary in Assignee's reasonable option in connection with prosecution, maintenance or enforcement or defense of any of the Patent Rights.
4. Agrees that the terms, covenants and conditions of this Assignment shall inure to the benefit of Assignee, its successors, assigns and other legal representative and shall be binding upon Assignor and its successors, legal representatives and assigns.

Signed on the dates indicated beside our signatures:

Yissum Research Development Company of the Hebrew University of Jerusalem, LTD,

Signature: Rina Abramzon-Shmueli Date: 31.1.18

Name: Intellectual Property

Signatory Capacity: Dr. Yaron Daniely

Dr. Yaron Daniely
CEO of Yissum

Assignee hereby accepts this Assignment.

Saul Yedgar

Signature: Saul Yedgar Date: 31.01.2018

**SCHEDULE A:**

<u>COUNTRY</u>	<u>APPLICATION NUMBER</u>	<u>FILING DATE</u>	<u>Title</u>	<u>Yissum Ref</u>
U.S.A.	US 7,034,006	JAN. 10, 2001	Use of lipid conjugates in the treatment of disease	2510-03
U.S.A.	US 7,101,859	JUL. 28, 2003	Use of lipid conjugates in the treatment of disease	2510-09
U.S.A.	US 7,141,552	MAR. 2, 2004	Use of lipid conjugates in the treatment of disease	2510-10
U.S.A.	US 7,504,384	SEP. 8, 2005	Use of lipid conjugates in the treatment of infection	2510-21
U.S.A.	US 7,608,598	JUN. 27, 2006	Use of lipid conjugates in the treatment of conjunctivitis.	2510-37
U.S.A.	US 7,811,999	NOV. 17, 2004	Use of lipid conjugates in the treatment of disease	2510-13
U.S.A.	US 8,076,312	NOV. 23, 2005	Use of lipid conjugates in the treatment of disease	2510-42
U.S.A.	US 8,304,395	JUL. 5, 2007	Use of lipid conjugates in the treatment of disease	2510-43
U.S.A.	US 8,372,815	OCT. 26, 2009	Use of lipid conjugates in the treatment of conjunctivitis	2510-55
U.S.A.	US 8,501,701	NOV. 14, 2006	Use of lipid conjugates in the treatment of disease	2510-39
U.S.A.	US 8,859,524	OCT. 27, 2011	Use of lipid conjugates in the treatment of chronic rhinosinusitis	2510-57
U.S.A.	US 8,865,681	NOV. 14, 2007	Use of lipid conjugates in the treatment of disease or disorders of the eye	3350-09
U.S.A.	US 8,883,761	MAR. 18, 2009	Use of lipid conjugates in the treatment of disease associated with vasculature.	—
U.S.A.	US 8,906,882	DEC. 12, 2011	Use of lipid conjugates in the treatment of allergic rhinitis.	2510-47
U.S.A.	US 9,040,078	AUG. 17, 2004	Use of lipid conjugates in the treatment of diseases of the central nervous system	2510-11
U.S.A.	US 20080113002 11/984,224	NOV. 17, 2007	Contact lens composition	3350-02
U.S.A.	US 2013/0316973 13/779,005	FEB. 27, 2013	Use of lipid conjugates in the treatment of cancer	—
U.S.A.	US 2014/0100190 14/071,578	NOV. 4, 2013	Use of lipid conjugates in the treatment of cystic fibrosis and applications thereof	3348-12
U.S.A.	US 2015/0057245 14/527,093	OCT. 29, 2014	Use of lipid conjugates in the treatment of Inflammatory disorders	—
U.S.A.	US 2015/0065467 14/478,519	SEPT. 5, 2014	Use of lipid conjugates in the treatment of disease or disorders of the eye	—

AUSTRALIA	AU 785017	JAN 10 2001	Use of Lipid Conjugates In the Treatment of Disease	2510-08
AUSTRALIA	AU 2011213739	JAN 10 2001	Use of lipid conjugates in the treatment of disease	-----
AUSTRALIA	AU 2010247105	MAY 11 2010	USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASES ASSOCIATED WITH VASCULATURE	3702-09
AUSTRALIA	AU 2014200908	FEB 21, 2014	USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASE	-----
AUSTRALIA	AU 2006278657	AUG 1, 2006	Use of Lipid Conjugates in Cystic Fibrosis and Applications Thereof	3348-11
AUSTRALIA	AU 2012254842 PCT/IL2012/050168	MAY 10, 2012	Liposomes comprising polymer-conjugated lipids and related uses	
AUSTRALIA	AU 2010247814	MAY 11, 2010	LIPID-POLYMER CONJUGATES, THEIR PREPARATION AND USES	3860-03
AUSTRALIA	AU 2013202151	OCT 28 2012	Lipid conjugates in the treatment of chronic rhinosinusitis	-----
BRAZIL	BR 112014009979-0	OCT 28 2012	conjugados de lipídios no tratamento de rinossinite crônica	-----
BRAZIL	BR 1120130291206	MAY 10, 2012	LIPOSOMES COMPRISING POLYMER-CONJUGATED LIPIDS AND RELATED USES	4097-07
CANADA	CA 2,397,016	JAN 10 2001	Use of Lipid Conjugates In the Treatment of Disease	2510-04
CANADA	CA 2,761,605	MAY 11 2010	USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASES ASSOCIATED WITH VASCULATURE	3702-08
CANADA	CA 2,617,484	AUG 1, 2006	Use of Lipid Conjugates in Cystic Fibrosis and Applications Thereof	3348-10
CANADA	CA 2,705,785	NOV 14, 2007	Use of Lipid Conjugates in the Treatment of Diseases or Disorders of the Eye	3350-10
CANADA	CA 2,851,476	OCT 28 2012	LIPID CONJUGATES IN THE TREATMENT OF CHRONIC RHINOSINUSITIS	-----
CHINA	CN 201080031101.5	MAY 11 2010	USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASES ASSOCIATED WITH VASCULATURE	3702-03
CHINA	CN 201280052090.8	OCT 28 2012	Use of Lipid Conjugates In the Treatment of Disease	2510-54
CHINA	CN 2007800498316		Use of Lipid Conjugates in the Treatment of Diseases or Disorders of the Eye	3350-07

CHINA	CN 201410436935.4	AUG 1, 2006	Use of lipid conjugates in cystic fibrosis and applications thereof	-----
CHINA	CN 201280022911.3	MAY 10, 2012	LIPOSOMES COMPRISING POLYMER-CONJUGATED LIPIDS AND RELATED USES	4097-05
CHINA	CN 080030467.0	MAY 11, 2010	LIPID-POLYMER CONJUGATES, THEIR PREPARATION AND USES	3860-02
EUROPE	EP- 14180931.9	JAN 10 2001	Use of lipid conjugates in the treatment of disease	-----
EUROPE	EP 10774611.7	NOV 11, 2010	USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASES ASSOCIATED WITH VASCULATURE	3702-06
EUROPE	EP 12844637.4 PCT/IL2012/050423	OCT 28 2012	Conjugués lipidiques dans le traitement de la rhinosinusite chronique	-----
EUROPE	EP 06800600.6	AUG 1, 2006	Use of Lipid Conjugates in Cystic Fibrosis and Applications Thereof	3348-08
HONG KONG	HK- 7109751.3	JAN 10 2001	Use of Lipid Conjugates In the Treatment of Disease	-----
HONG KONG	HK 12108755.4	MAY 11 2010	USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASES ASSOCIATED WITH VASCULATURE	3702-05
HONG KONG	HK 14108715.1	MAY 10, 2012	LIPOSOMES COMPRISING POLYMER-CONJUGATED LIPIDS AND RELATED USES	
HONG KONG	HK 12107161.4	MAY 11, 2010	LIPID-POLYMER CONJUGATES, THEIR PREPARATION AND USES	3860-07
INDIA	IN2997/CHENP/2014	OCT 28 2012	Use of lipid conjugates in the treatment of chronic rhinosinusitis	-----
ISRAEL	IL 150628	JAN 10 2001	Use of Lipid Conjugates In the Treatment of Disease	2510-06
ISRAEL	IL 189171	AUG 1, 2006	Use of Lipid Conjugates in Cystic Fibrosis and Applications Thereof	3348-07
ISRAEL	IL 216203	MAY 11, 2010	LIPID-POLYMER CONJUGATES, THEIR PREPARATION AND USES	3860-05
ISRAEL	IL 216205	MAY 11 2010	USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASES ASSOCIATED WITH VASCULATURE	3702-04
ISRAEL	IL 229325	MAY 10, 2012	LIPOSOMES COMPRISING POLYMER-CONJUGATED LIPIDS AND RELATED USES	4097-02
ISRAEL	IL 232250	OCT 28 2012	Use of Lipid Conjugates In the Treatment of Disease	2510-52

JAPAN	JP 4782966	JAN 10 2001	USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASE	-----
JAPAN	JP 5581265	JAN 10 2001	Use of lipid conjugates in the treatment of disease	-----
JAPAN	JP 2008-525110	AUG 1, 2006	Use of Lipid Conjugates in Cystic Fibrosis and Applications Thereof	3348-06
JAPAN	JP 2012-510384	MAY 11 2010	USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASES ASSOCIATED WITH VASCULATURE	3702-07
JAPAN	JP 2012-510916	MAY 11, 2010	LIPID-POLYMER CONJUGATES, THEIR PREPARATION AND USES	
JAPAN	JP 2013-11660	AUG 1, 2006	Use of Lipid Conjugates in Cystic Fibrosis and Applications Thereof	3348-13
JAPAN	JP 2013-212528		Use of Lipid Conjugates In the Treatment of Disease	2510-50
JAPAN	JP 2014-509889	MAY 10, 2012	LIPOSOMES COMPRISING POLYMER-CONJUGATED LIPIDS AND RELATED USES	
JAPAN	JP 2014-537812		Use of lipid conjugates in the treatment of chronic rhinosinusitis	-----